LEADER 03448nam 2200685 a 450 001 9910783139403321 005 20231110230259.0 010 $a1-280-19787-0 010 $a9786610197873 010 $a1-4051-4606-0 010 $a1-4237-1777-5 035 $a(CKB)1000000000009157 035 $a(EBL)233112 035 $a(OCoLC)475939740 035 $a(SSID)ssj0000257608 035 $a(PQKBManifestationID)11193224 035 $a(PQKBTitleCode)TC0000257608 035 $a(PQKBWorkID)10254089 035 $a(PQKB)11471854 035 $a(Au-PeEL)EBL233112 035 $a(CaPaEBR)ebr10033058 035 $a(OCoLC)437147416 035 $a(Au-PeEL)EBL5247562 035 $a(CaONFJC)MIL19787 035 $a(Au-PeEL)EBL7104542 035 $a(MiAaPQ)EBC233112 035 $a(EXLCZ)991000000000009157 100 $a20030609d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe textbook of pharmaceutical medicine$b[electronic resource] 205 $a4th ed. /$bedited by John P. Griffin and John O'Grady. 210 $aLondon $cBMJ Books$d2002 215 $a1 online resource (896 p.) 225 1 $aNew York Academy of Sciences 300 $aIncludes index. 300 $aPrevious ed.: / edited by J.P. Griffin, J. O'Grady, P.F. D'Arcy. Belfast : Queen's University of Belfast, c1998. 311 $a0-7279-1523-1 327 $aContents; Contributors; Preface; Acknowledgements; The editors; 1: Discovery of new medicines; 2: Pharmaceutical development; 3: Toxicity testing; 4: Exploratory development; 5: Clinical pharmacokinetics; 6: Clinical trials and good clinical practice; 7: Medical statistics; 8: Development of medicines: full development; 9: The medical department; 10: Medical marketing; 11: Information and promotion; 12: The supply of unlicensed medicines for particular patient use; 13: Legal and ethical issues relating to medicinal products; 14: The safety of medicines 327 $a15: The development of the control of human medicines in Europe from classical times to the year 200016: Technical requirements for registration of pharmaceuticals for human use: the ICH process and the common technical document; 17: The regulation of drug products by the United States Food and Drug Administration; 18: The US FDA in the drug development, evaluation and approval process; 19: Regulatory and clinical trial systems in Japan; 20: Economics of healthcare; 21: Controls on NHS medicines prescribing and expenditure in the UK (a historical perspective); Appendix 1; Appendix 2 327 $aPRESCRIPTION MEDICINES CODE OF PRACTICE AUTHORITY Constitution and ProcedureIndex 330 $aThis edition has totally revised chapters on drug regulation in the USA, with new contributor, Dr Peter Barton Hutt formerly FDA Special Counsel. New contributions regarding pharmaco-economics are covered in two new chapters. 410 0$aNew York Academy of Sciences 606 $aPharmaceutical chemistry 606 $aPharmacology 615 0$aPharmaceutical chemistry. 615 0$aPharmacology. 676 $a615.1 701 $aGriffin$b J. P$g(John Parry)$0857365 701 $aO'Grady$b John$0857366 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910783139403321 996 $aThe textbook of pharmaceutical medicine$93703835 997 $aUNINA